Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 23 August 2018 | By Ana Mulero
To do this, we’re announcing the 4th year of the voluntary Experiential Learning Site Visit (ELSV) program to provide our staff with an in-person understanding of the industry, its operations, and challenges that impact a drug’s development and life cycle. https://t.co/X9FQ4EJ4u0 — Scott Gottlieb, M.D. (@SGottliebFDA) August 23, 2018
To do this, we’re announcing the 4th year of the voluntary Experiential Learning Site Visit (ELSV) program to provide our staff with an in-person understanding of the industry, its operations, and challenges that impact a drug’s development and life cycle. https://t.co/X9FQ4EJ4u0
We encourage companies engaging in the development and manufacturing of both active pharmaceutical ingredients and finished drug products to respond for FY 2019. Full criteria for entry and notable dates for the program can be found here: https://t.co/X9FQ4Ert5q — Scott Gottlieb, M.D. (@SGottliebFDA) August 23, 2018
We encourage companies engaging in the development and manufacturing of both active pharmaceutical ingredients and finished drug products to respond for FY 2019. Full criteria for entry and notable dates for the program can be found here: https://t.co/X9FQ4Ert5q